Fierce Biotech

1 day ago | fiercebiotech.com | Darren Incorvaia

Bayer is boosting its precision oncology efforts with a molecular database from health tech firm ConcertAI. Under a multi-year deal, Bayer will gain access to ConcertAI’s Translational360 database, along with the company’s analytical AI software, according to an April 22 release. Translational360 combines clinical, genomic, transcriptomic and imaging data, with the goal of helping researchers choose drug programs and design clinical trials more efficiently.

1 day ago | fiercebiotech.com | Darren Incorvaia

The Department of Health and Human Services (HHS) is cutting off funding to the long-running Women’s Health Initiative (WHI) in September, a move that leaves the fate of one of the world's largest women’s health studies hanging in the balance. The agency is canceling contracts to the WHI’s regional centers by the end of September, the WHI said in an April 21 announcement.

1 day ago | fiercebiotech.com | Darren Incorvaia

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted medicines in the autoimmune disease space. Flagship Pioneering-backed Repertoire will leverage its immune-modeling platform in efforts to discover new targets in an undisclosed autoimmune condition, after which Genentech will take over preclinical and clinical development plus any potential commercialization activities, according to an April 23 release.

3 days ago | fiercebiotech.com | Gabrielle Masson |Darren Incorvaia

The National Institutes of Health (NIH) is rolling out rules that block new grants for any researcher or institution advancing programs related to diversity, equity and inclusion (DEI). The new rule also prohibits grant recipients from participating in boycotts against Israel, which includes cutting off or limiting commercial activity with Israeli companies. The new “Civils Rights term” applies to all current terms and conditions for NIH grants, according to an April 21 notice.

3 days ago | fiercebiotech.com | Gabrielle Masson |Darren Incorvaia

The National Institutes of Health (NIH) is halting new grant and contract payments to several universities, a move the agency has been instructed not to disclose to affected schools, according to several reports. Disbursements have been halted to Harvard University, Brown University, Northwestern University and Cornell University, plus Weill-Cornell Medical School, according to an April 16 NIH email viewed by Science.